Cargando…
Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells
BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo prac...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521132/ https://www.ncbi.nlm.nih.gov/pubmed/28748102 http://dx.doi.org/10.1186/s40780-017-0090-y |
_version_ | 1783251922993545216 |
---|---|
author | Konaka, Ken Moriyama, Kota Sakurada, Takumi Okada, Naoto Imanishi, Masaki Zamami, Yoshito Kawazoe, Kazuyoshi Fushitani, Shuji Ishizawa, Keisuke |
author_facet | Konaka, Ken Moriyama, Kota Sakurada, Takumi Okada, Naoto Imanishi, Masaki Zamami, Yoshito Kawazoe, Kazuyoshi Fushitani, Shuji Ishizawa, Keisuke |
author_sort | Konaka, Ken |
collection | PubMed |
description | BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo practitioners have suggested that it may be possible to counteract such side effects, we analyzed the effects of Kamishoyosan, Shakuyakukanzoto, and Goshajinkigan in an in vitro model of paclitaxel-induced peripheral neuropathy. METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo. We also compared phosphorylation of extracellular signal-regulated kinase (Erk)1/2 and Akt via Western blot analysis. About effect of kampo to anticancer efficacy, we confirmed cell cytotoxicity in A549 cells using MTT assay. RESULTS: Addition of Kamishoyosan or Shakuyakukanzoto, but not Goshajinkigan, significantly improved neurite length and GAP-43 and NF-L levels from paclitaxel-treated PC12 cells, relative to those of only NGF-treated PC12 cells. The promoting effect of Kamishoyosan and Shakuyakukanzoto in neurite outgrowth is confirmed when NGF promoted neurite outgrowth, and it was inhibited partially when Erk1/2 and Akt were blocked by Erk1/2 inhibitor or Akt inhibitor alone. Furthermore, neurite outgrowth induced by TJ24 and TJ68 was inhibited more strongly when Erk1/2 inhibitor and Akt inhibitor were treated at the same time. NGF with Kamishoyosan or Shakuyakukanzoto promoted the proportion of phosphorylated Erk1/2 and phosphorylated Akt compare with NGF only. On the other hand, Kamishoyosan or Shakuyakukanzoto didn’t influence cytotoxicity of paclitaxel in A549 cells. CONCLUSIONS: Kamishoyosan or Shakuyakukanzoto promotes neurite outgrowth with NGF via increasing the proportion of phosphorylated Erk1/2 and phosphorylated Akt in PC12 cells. The effect applies to recovery from paclitaxel-induced axonal involvement and might promote recovery from paclitaxel-induced neuropathy without influence of anticancer effect of paclitaxel. |
format | Online Article Text |
id | pubmed-5521132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55211322017-07-26 Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells Konaka, Ken Moriyama, Kota Sakurada, Takumi Okada, Naoto Imanishi, Masaki Zamami, Yoshito Kawazoe, Kazuyoshi Fushitani, Shuji Ishizawa, Keisuke J Pharm Health Care Sci Research Article BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo practitioners have suggested that it may be possible to counteract such side effects, we analyzed the effects of Kamishoyosan, Shakuyakukanzoto, and Goshajinkigan in an in vitro model of paclitaxel-induced peripheral neuropathy. METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo. We also compared phosphorylation of extracellular signal-regulated kinase (Erk)1/2 and Akt via Western blot analysis. About effect of kampo to anticancer efficacy, we confirmed cell cytotoxicity in A549 cells using MTT assay. RESULTS: Addition of Kamishoyosan or Shakuyakukanzoto, but not Goshajinkigan, significantly improved neurite length and GAP-43 and NF-L levels from paclitaxel-treated PC12 cells, relative to those of only NGF-treated PC12 cells. The promoting effect of Kamishoyosan and Shakuyakukanzoto in neurite outgrowth is confirmed when NGF promoted neurite outgrowth, and it was inhibited partially when Erk1/2 and Akt were blocked by Erk1/2 inhibitor or Akt inhibitor alone. Furthermore, neurite outgrowth induced by TJ24 and TJ68 was inhibited more strongly when Erk1/2 inhibitor and Akt inhibitor were treated at the same time. NGF with Kamishoyosan or Shakuyakukanzoto promoted the proportion of phosphorylated Erk1/2 and phosphorylated Akt compare with NGF only. On the other hand, Kamishoyosan or Shakuyakukanzoto didn’t influence cytotoxicity of paclitaxel in A549 cells. CONCLUSIONS: Kamishoyosan or Shakuyakukanzoto promotes neurite outgrowth with NGF via increasing the proportion of phosphorylated Erk1/2 and phosphorylated Akt in PC12 cells. The effect applies to recovery from paclitaxel-induced axonal involvement and might promote recovery from paclitaxel-induced neuropathy without influence of anticancer effect of paclitaxel. BioMed Central 2017-07-21 /pmc/articles/PMC5521132/ /pubmed/28748102 http://dx.doi.org/10.1186/s40780-017-0090-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Konaka, Ken Moriyama, Kota Sakurada, Takumi Okada, Naoto Imanishi, Masaki Zamami, Yoshito Kawazoe, Kazuyoshi Fushitani, Shuji Ishizawa, Keisuke Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells |
title | Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells |
title_full | Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells |
title_fullStr | Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells |
title_full_unstemmed | Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells |
title_short | Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells |
title_sort | kamishoyosan and shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in pc12 cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521132/ https://www.ncbi.nlm.nih.gov/pubmed/28748102 http://dx.doi.org/10.1186/s40780-017-0090-y |
work_keys_str_mv | AT konakaken kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells AT moriyamakota kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells AT sakuradatakumi kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells AT okadanaoto kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells AT imanishimasaki kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells AT zamamiyoshito kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells AT kawazoekazuyoshi kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells AT fushitanishuji kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells AT ishizawakeisuke kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells |